
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc demonstrates a compelling investment opportunity due to its attractive current valuation, with an increased net present value (NPV) analysis indicating substantial upside potential. The company's lead candidate, stenoparib, offers promising clinical outcomes, particularly with new data revealing a median overall survival exceeding 25 months for patients with advanced recurrent ovarian cancer and limited treatment alternatives. Additionally, the integration of proprietary Drug Response Predictor (DRP) technology enhances patient selection, likely leading to improved clinical outcomes and supporting the company's growth trajectory in the precision medicine space.
Bears say
Allarity Therapeutics Inc. reported a net loss of $2.8 million, translating to an earnings per share (EPS) of $(0.19), which is slightly better than estimates but still reflects significant financial strain. The ongoing development of stenoparib is burdened by substantial risks, including potential failures in clinical trials, challenges in obtaining regulatory approvals, and issues related to market competition and reimbursement. Furthermore, liquidity and balance sheet risks pose additional concerns that may hinder the company's ability to sustain operations and achieve its growth objectives.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares